Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.58 |
| ▸ | MAP2 | P11137 | 1/20 | 0.56 |
| ▸ | KIT | P10721 | 4/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | TEK | Q02763 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1880344 | 0.88 | MAP2 (0.59) | KDRPDGFRBMAP2KITFLT3 | |
| SCHEMBL3888761 | 0.88 | KDR (0.74) | KDRPDGFRBMAP2KITFLT3 | |
| SCHEMBL1880291 | 0.86 | MAP2 (0.59) | KDRMAP2KITFLT3ROCK2 | |
| SCHEMBL1876149 | 0.86 | MAP2 (0.59) | KDRPDGFRBMAP2KITFLT3 | |
| SCHEMBL4068130 | 0.85 | MAP2 (0.56) | KDRPDGFRBMAP2KITFLT3 | |
| SCHEMBL1878953 | 0.85 | KDR (0.60) | KDRPDGFRBKITFLT3AURKA | |
| SCHEMBL1881945 | 0.84 | MAP2 (0.58) | KDRPDGFRBMAP2KITFLT3 | |
| SCHEMBL1878205 | 0.83 | KDR (0.58) | KDRPDGFRBMAP2KITFLT3 | |
| SCHEMBL1877293 | 0.83 | MAP2 (0.63) | KDRPDGFRBMAP2KITFLT3 | |
| SCHEMBL1880879 | 0.82 | MAP2 (0.60) | KDRPDGFRBMAP2KITFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947706-B2 | Anticancer agents; modulate kinases such as KDR (Kinase insert Domain Receptor and Tie-2 (TEK) , a member of the tyrosine kinase receptor family; 3-{4-[3-(2-methoxyphenyl)ureido]phenyl}-1H-pyrrolo[2,3-b]pyridine-2-carboxamide for example | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-05-24 | — | — | US | claimed |
| EP-1877409-B1 | SUBSTITUTED PYRROLO-PYRIDINES, COMPOSITION CONTAINING THEM, METHOD FOR THEIR PRODUCING AND USE THEREOF | AVENTIS PHARMA SA (FR) | 2009-06-17 | — | — | EP | claimed |
| US-20080139606-A1 | Substituted Pyrrolopyridines, Compositions Containing Them, Manufacturing Process Therefor and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-06-12 | — | — | US | claimed |
| EP-1877409-A2 | SUBSTITUTED PYRROLO-PYRIDINES, COMPOSITION CONTAINING THEM, METHOD FOR THEIR PRODUCING AND USE THEREOF | Aventis Pharma S.A. (FR) | 2008-01-16 | — | — | EP | claimed |
| WO-2006114520-A2 | SUBSTITUTED PYRROLO-PYRIDINES, COMPOSITION CONTAINING THEM, METHOD FOR THEIR PRODUCING AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2006-11-02 | — | — | WO | claimed |
| US-7947706-B2 | Anticancer agents; modulate kinases such as KDR (Kinase insert Domain Receptor and Tie-2 (TEK) , a member of the tyrosine kinase receptor family; 3-{4-[3-(2-methoxyphenyl)ureido]phenyl}-1H-pyrrolo[2,3-b]pyridine-2-carboxamide for example | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-05-24 | — | — | US | disclosed |
| US-7947706-B2 | Anticancer agents; modulate kinases such as KDR (Kinase insert Domain Receptor and Tie-2 (TEK) , a member of the tyrosine kinase receptor family; 3-{4-[3-(2-methoxyphenyl)ureido]phenyl}-1H-pyrrolo[2,3-b]pyridine-2-carboxamide for example | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-05-24 | — | — | US | disclosed |
| US-7947706-B2 | Anticancer agents; modulate kinases such as KDR (Kinase insert Domain Receptor and Tie-2 (TEK) , a member of the tyrosine kinase receptor family; 3-{4-[3-(2-methoxyphenyl)ureido]phenyl}-1H-pyrrolo[2,3-b]pyridine-2-carboxamide for example | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-05-24 | — | — | US | disclosed |
| EP-1877409-B1 | SUBSTITUTED PYRROLO-PYRIDINES, COMPOSITION CONTAINING THEM, METHOD FOR THEIR PRODUCING AND USE THEREOF | AVENTIS PHARMA SA (FR) | 2009-06-17 | — | — | EP | disclosed |
| US-20080139606-A1 | Substituted Pyrrolopyridines, Compositions Containing Them, Manufacturing Process Therefor and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-06-12 | — | — | US | disclosed |
| US-20080139606-A1 | Substituted Pyrrolopyridines, Compositions Containing Them, Manufacturing Process Therefor and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-06-12 | — | — | US | disclosed |
| US-20080139606-A1 | Substituted Pyrrolopyridines, Compositions Containing Them, Manufacturing Process Therefor and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-06-12 | — | — | US | disclosed |
| EP-1877409-A2 | SUBSTITUTED PYRROLO-PYRIDINES, COMPOSITION CONTAINING THEM, METHOD FOR THEIR PRODUCING AND USE THEREOF | Aventis Pharma S.A. (FR) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006114520-A2 | SUBSTITUTED PYRROLO-PYRIDINES, COMPOSITION CONTAINING THEM, METHOD FOR THEIR PRODUCING AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139606-A1 | Substituted Pyrrolopyridines, Compositions Containing Them, Manufacturing Process Therefor and Use Thereof | WEE1, CNKSR1, WEE2 | KDR 1024/4885PDGFRB 780/4885MAP2 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.